Isidro B Salusky

List of Publications by Year
in descending order

77 papers	3,646 citations	186265 28 h-index	133252 59 g-index
81 all docs	81 docs citations	81 times ranked	2559 citing authors

#	Article	IF	Citations
1	Hepcidinâ€"A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1051-1056.	4.5	279
2	Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone, 2009, 45, 1161-1168.	2.9	239
3	Circulating Fibroblast Growth Factor 23 in Patients with End-Stage Renal Disease Treated by Peritoneal Dialysis Is Intact and Biologically Active. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 578-585.	3.6	205
4	Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney International, 1994, 45, 253-258.	5.2	185
5	Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney International, 1988, 33, 975-982.	5.2	159
6	Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney International, 2011, 79, 112-119.	5.2	148
7	Early Skeletal and Biochemical Alterations in Pediatric Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 146-152.	4.5	144
8	Relationship between Plasma Fibroblast Growth Factor-23 Concentration and Bone Mineralization in Children with Renal Failure on Peritoneal Dialysis. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 511-517.	3.6	137
9	Bone disease in children and adolescents undergoing successful renal transplantation. Kidney International, 1998, 53, 1358-1364.	5.2	136
10	Disordered FGF23 and Mineral Metabolism in Children with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 344-353.	4.5	128
11	Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney International, 2003, 63, 1801-1808.	5.2	119
12	Fracture Burden and Risk Factors in Childhood CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 543-550.	6.1	107
13	Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica, 2017, 102, e427-e430.	3.5	93
14	Value of the New Bone Classification System in Pediatric Renal Osteodystrophy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1860-1866.	4.5	92
15	Sevelamer Controls Parathyroid Hormoneâ€"Induced Bone Disease as Efficiently as Calcium Carbonate without Increasing Serum Calcium Levels during Therapy with Active Vitamin D Sterols. Journal of the American Society of Nephrology: JASN, 2005, 16, 2501-2508.	6.1	84
16	Cardiovascular calcification in endâ€stage renal disease. Nephrology Dialysis Transplantation, 2002, 17, 336-339.	0.7	83
17	Growth Retardation in Children with Chronic Renal Failure. Journal of Bone and Mineral Research, 1999, 14, 1680-1690.	2.8	77
18	Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrology Dialysis Transplantation, 2019, 34, 2057-2065.	0.7	73

#	Article	IF	Citations
19	FGF23 and Left Ventricular Hypertrophy in Children with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 45-52.	4.5	72
20	Adynamic Renal Osteodystrophy. Journal of the American Society of Nephrology: JASN, 2001, 12, 1978-1985.	6.1	68
21	Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1989-1998.	4.5	64
22	Technical Approach to Iliac Crest Biopsy. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, S164-S169.	4.5	56
23	Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. American Journal of Physiology - Renal Physiology, 2016, 311, F1369-F1377.	2.7	54
24	Fourâ€dimensional, multiphase, steadyâ€state imaging with contrast enhancement (MUSIC) in the heart: A feasibility study in children. Magnetic Resonance in Medicine, 2015, 74, 1042-1049.	3.0	49
25	FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrology Dialysis Transplantation, 2014, 29, 1525-1532.	0.7	46
26	MRI with ferumoxytol: A single center experience of safety across the age spectrum. Journal of Magnetic Resonance Imaging, 2017, 45, 804-812.	3.4	40
27	Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica, 2018, 103, e141-e142.	3.5	38
28	Psychological distress and treatment adherence among children on dialysis. Pediatric Nephrology, 1997, 11, 604-606.	1.7	32
29	Are new vitamin D analogues in renal bone disease superior to calcitriol?. Pediatric Nephrology, 2005, 20, 393-398.	1.7	32
30	Racialâ€"ethnic disparities in mortality and kidney transplant outcomes among pediatric dialysis patients. Pediatric Nephrology, 2017, 32, 685-695.	1.7	32
31	Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients. Pediatric Nephrology, 2016, 31, 661-669.	1.7	30
32	Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol. Pediatric Radiology, 2016, 46, 1332-1340.	2.0	28
33	Impaired osteocyte maturation in the pathogenesis of renal osteodystrophy. Kidney International, 2018, 94, 1002-1012.	5.2	26
34	Antibacterial Responses by Peritoneal Macrophages Are Enhanced Following Vitamin D Supplementation. PLoS ONE, 2014, 9, e116530.	2.5	26
35	Special aspects of renal osteodystrophy in children. Seminars in Nephrology, 2004, 24, 69-77.	1.6	24
36	Mechanism of Action and Clinical Attributes of AuryxiaÂ® (Ferric Citrate). Drugs, 2019, 79, 957-968.	10.9	24

#	Article	IF	Citations
37	Non-renal-Related Mechanisms of FGF23 Pathophysiology. Current Osteoporosis Reports, 2018, 16, 724-729.	3.6	23
38	Osteocytic Protein Expression Response to Doxercalciferol Therapy in Pediatric Dialysis Patients. PLoS ONE, 2015, 10, e0120856.	2.5	22
39	Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo. Kidney International, 2015, 87, 593-601.	5.2	22
40	Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder. Current Osteoporosis Reports, 2017, 15, 198-206.	3.6	22
41	Lipoproteins in Children Treated with Continuous Peritoneal Dialysis. Pediatric Research, 1991, 29, 155-159.	2.3	21
42	Vitamin D sterols increase FGF23 expression by stimulating osteoblast and osteocyte maturation in CKD bone. Bone, 2019, 127, 626-634.	2.9	21
43	The management of renal osteodystrophy. Pediatric Nephrology, 1996, 10, 651-653.	1.7	20
44	Idiopathic juvenile osteoporosis: a cross-sectional single-centre experience with bone histomorphometry and quantitative computed tomography. Pediatric Rheumatology, 2013, 11, 6.	2.1	20
45	Skeletal Consequences of Nephropathic Cystinosis. Journal of Bone and Mineral Research, 2018, 33, 1870-1880.	2.8	20
46	Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling. ELife, 2022, 11, .	6.0	18
47	Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model. Haematologica, 2017, 102, e85-e88.	3.5	17
48	Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatric Nephrology, 2009, 24, 1355-1361.	1.7	16
49	An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28Âdays to <â€‰6Âyears with chronic kidney disease receiving dialysis. Pediatric Nephrology, 2019, 34, 145-154.	1.7	16
50	Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney International, 2021, 99, 977-985.	5.2	16
51	Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation. PLoS ONE, 2015, 10, e0138156.	2.5	16
52	Fractures and Osteomalacia in a Patient Treated With Frequent Home Hemodialysis. American Journal of Kidney Diseases, 2017, 70, 445-448.	1.9	13
53	Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients. Pediatric Nephrology, 2018, 33, 2137-2142.	1.7	13
54	Measurement of serum phosphate levels using a mobile sensor. Analyst, The, 2020, 145, 1841-1848.	3.5	13

#	Article	IF	Citations
55	Correspondence on â€œProspective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI)â€•by Ferreira et al.. Genetics in Medicine, 2021, 23, 2006-2007.	2.4	10
56	Nephropathic Cystinosis: A Distinct Form of CKDâ€"Mineral and Bone Disorder that Provides Novel Insights into the Regulation of FGF23. Journal of the American Society of Nephrology: JASN, 2020, 31, 2184-2192.	6.1	9
57	Vitamin C overload may contribute to systemic oxalosis in children receiving dialysis. Pediatric Nephrology, 2021, 36, 435-441.	1.7	9
58	Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis. Pediatric Nephrology, 2019, 34, 107-115.	1.7	7
59	Disodium ethylenediaminetetraacetate: adverse effects in dialyzed children. Pediatric Nephrology, 1993, 7, 182-184.	1.7	6
60	Parathyroid gland function in secondary hyperparathyroidism. Pediatric Nephrology, 1996, 10, 359-363.	1.7	6
61	Elevated Fibroblast Growth Factor 23 Levels Are Associated With Greater Diastolic Dysfunction in ESRD. Kidney International Reports, 2019, 4, 1748-1751.	0.8	6
62	Racial differences in bone histomorphometry in children and young adults treated with dialysis. Bone, 2019, 127, 114-119.	2.9	6
63	Bone Canopies in Pediatric Renal Osteodystrophy. PLoS ONE, 2016, 11, e0152871.	2.5	5
64	Unraveling the osteocyte in CKD-MBD postâ€"renal transplantation. Kidney International, 2019, 96, 1059-1061.	5.2	5
65	Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients. Kidney International Reports, 2019, 4, 1742-1748.	0.8	5
66	Optimal Management of Renal Osteodystrophy in Children Treated with CAPD and CCPD. Seminars in Dialysis, 1994, 7, 435-441.	1.3	3
67	Pediatric Renal Osteodystrophy. Seminars in Dialysis, 1996, 9, 347-352.	1.3	1
68	Combining exercise and growth hormone therapy: how can we translate from animal models to chronic kidney disease children?. Nephrology Dialysis Transplantation, 2016, 31, 1191-1194.	0.7	1
69	Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis. Pediatric Nephrology, 2021, 36, 133-142.	1.7	1
70	Regional variation in bone turnover at the iliac crest versus the greater trochanter. Bone, 2021, 143, 115604.	2.9	1
71	Development of a translational research pathway at the David Geffen School of Medicine University of California, Los Angeles. International Journal of Medical Education, 2017, 8, 334-335.	1.2	1
72	Effects of Primary Kidney Disease Etiology on Renal Osteodystrophy in Pediatric Dialysis Patients. JBMR Plus, 2022, 6, e10601.	2.7	1

#	Article	IF	Citations
73	A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial. Pediatric Nephrology, 2022, 37, 2547-2557.	1.7	1
74	Reply to the letter from J. I. Minguela and R. Ruiz-de-Gauna. Pediatric Nephrology, 2004, 19, 947.	1.7	0
75	The Authors Reply. Kidney International Reports, 2020, 5, 1119-1120.	0.8	0
76	Bone marrow adiposity inversely correlates with bone turnover in pediatric renal osteodystrophy. Bone Reports, 2021, 15, 101104.	0.4	0
77	Aluminium-related Bone Disease in Children with Renal Failure. , 1998, , 109-132.		0